Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H40O7 |
Molecular Weight | 500.6237 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)C(C)(C)C
InChI
InChIKey=FAPMGCFSVXGXMO-FHKBAQRKSA-N
InChI=1S/C29H40O7/c1-25(2,3)24(33)34-15-21(32)29-22(35-26(4,5)36-29)13-19-18-9-8-16-12-17(30)10-11-27(16,6)23(18)20(31)14-28(19,29)7/h10-12,18-20,22-23,31H,8-9,13-15H2,1-7H3/t18-,19-,20-,22+,23+,27-,28-,29+/m0/s1
Molecular Formula | C29H40O7 |
Molecular Weight | 500.6237 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DESONIDE Approved UseDesonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
Doses
Dose | Population | Adverse events |
---|---|---|
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.3 |
unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: Page: p.3 |
Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: Page: p.3 |
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: Page: p.1Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Telangiectasia | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.3 |
unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: Page: p.3 |
Acneiform eruption | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Allergic contact dermatitis | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Atrophy | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Cushing's syndrome | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Hypothalamic pituitary adrenal axis suppression | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Irritation skin | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Skin hypopigmentation | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Striae | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4,8 |
yes | yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Page: 4,8 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis. | 1982 |
|
Allergic contact dermatitis from topical corticosteroids. | 1989 Aug |
|
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. | 2002 |
|
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. | 2002 Jul |
|
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare. | 2004 Sep |
|
Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study. | 2004 Sep-Oct |
|
[Connubial contact dermatitis to an inhaled corticosteroid]. | 2005 Feb |
|
Comparison of the analysis of corticosteroids using different techniques. | 2005 Jan |
|
Seborrheic dermatitis. | 2005 Jan-Feb |
|
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. | 2005 Mar-Apr |
|
Rapid resolution of a common problem. | 2005 May |
|
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug. | 2006 Jun |
|
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. | 2007 Jun |
|
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. | 2008 Aug |
|
What's your assessment? Severe seborrheic dermatitis. | 2008 Dec |
|
Desonide: a review of formulations, efficacy and safety. | 2008 Jul |
|
[Streptococcal perianal dermatitis and guttate psoriasis]. | 2009 Jan |
|
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. | 2009 Jul 2 |
|
Manifestations of cutaneous sarcoidosis: a case report of an African American woman. | 2009 Jun |
|
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. | 2009 Nov-Dec |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. | 2010 Apr |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
Update on the management of chronic eczema: new approaches and emerging treatment options. | 2010 Jul 28 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:07:00 GMT 2023
by
admin
on
Sat Dec 16 10:07:00 GMT 2023
|
Record UNII |
UB3LO24HGK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034982
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
UB3LO24HGK
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
DTXSID00229315
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
71300443
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
78806-68-5
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |